Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenit...
Saved in:
Main Authors: | Anick Bérard, Shannon Strom, Jin-Ping Zhao, Shashi Kori, Detlef Albrecht |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/8872f81c01f84aba9c5de34e563332be |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevalence and duration of prescribed opioid use during pregnancy: a cohort study from the Quebec Pregnancy Cohort
by: Jin-Ping Zhao, et al.
Published: (2021) -
Associations of early pregnancy BMI with adverse pregnancy outcomes and infant neurocognitive development
by: Yu-Ting Chen, et al.
Published: (2021) -
Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
by: Fatima Tauqeer, et al.
Published: (2021) -
Association of maternal pre-pregnancy low or increased body mass index with adverse pregnancy outcomes
by: Jie Tang, et al.
Published: (2021) -
Asthma during pregnancy in a population-based study--pregnancy complications and adverse perinatal outcomes.
by: Gustaf Rejnö, et al.
Published: (2014)